欢迎分享，转载有版权, 快快登录 lingmed.net/reports 获取更多项目信息吧！
从本周开始，灵麦医药将推出一系列专题报告，针对热门适应症领域，进行深入分析。今天我们首先来谈谈多发性硬化的全球市场及竞争格局。
报告亮点：
多发性硬化（multiple sclerosis，MS）是以中枢神经系统白质炎性脱髓鞘病变为主要特点的自身免疫病。
全球约有250万多发性硬化患者，中国属于多发性硬化低发区。
2016年，全球多发性硬化药品总销售额为218亿美金。根据EvaluatePharma的权威预估，2022年该市场将达到220亿美元。
全球多发性硬化市场竞争较为激烈。2016年与2022年的市场格局变化较大。根据EvaluatePharma权威分析，罗氏的Ocrevus会在2022年以42.15亿夺下销量冠军。
反观中国市场，全球多发性硬化药品销量前十的产品仅有拜耳的β干扰素在中国已经注册上市。
根据Biotechgate博谷数据库显示，现在有103个多发性硬化相关的项目正在全球寻找合作伙伴，其中临床Ⅱ期以后的项目有34个。
想要下载完整报告或对其它治疗领域感兴趣？
速速点击文末‘阅读原文’下载吧！
Lingmed Indication report- Multiple sclerosis
From this week, Lingmed will share a series of market analysis report targeting on hot indication area. We will start with multiple sclerosis this week.
Report highlights:
Multiple Sclerosis (MS) is a chronic neurological disorder where the myelin sheath (a fatty substance insulating the nerve fibers) is destroyed.
There are approximately 2.5 million people are affected with multiple sclerosis worldwide.
According to EvaluatePharma, the total sales for MS market is around 21.8 billion in 2016. The sales will reach 22 billion in 2022.
According to EvaluatePharma, Ocrevus(Roche) will set to climb to number one position in MS drug sales to 2022.
While in China, Bayer's Betaferon (interferon beta-1b) is described as the only therapy available in China that can reduce the seizure frequency and nerve damage associated with MS.
According to Biotechgate, there are 103 MS related assets looking for partner worldwide, among which 34 assets are after phase II.
If you are interested in the full report or any other indication area, please click 'read more' to download.
灵麦医药是以下两家情报数据库在中国的独家合作伙伴：
Biotechgate/博谷 - 全球创新药和器械产品收购和引进数据库
EvaluatePharma/预估医药 - 全球医药研发、销售、市场预估等竞争情报数据库
想要下载完整报告?
请登录 www.lingmed.net/reports
或点击下方“阅读原文”马上下载